Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 3/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466767 | 0.76 | LMNA (0.51) | LMNAPOLBATRRXFP1 | |
| SCHEMBL24366932 | 0.74 | LMNA (0.40) | LMNAPOLBARATRCACNA1H | |
| SCHEMBL15660587 | 0.74 | AAK1 (0.41) | LMNAPOLBARATRCACNA1H | |
| SCHEMBL29477586 | 0.74 | LMNA (0.40) | LMNAPOLBARATRCACNA1H | |
| SCHEMBL2067993 | 0.72 | ALDH1A1 (0.37) | — | |
| SCHEMBL20839513 | 0.72 | ATR (0.42) | LMNAPOLBATRRXFP1NPSR1 | |
| SCHEMBL15687760 | 0.70 | JUN (0.45) | LMNAPOLBARATRCACNA1H | |
| SCHEMBL29081695 | 0.70 | ALDH1A1 (0.49) | LMNAPOLBAR | |
| SCHEMBL29477833 | 0.70 | ALDH1A1 (0.49) | LMNAPOLBAR | |
| SCHEMBL15264820 | 0.70 | ATR (0.48) | ATRNPSR1CYP17A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| CN-101754968-A | Substituted imidazopyridazines as PI3K lipid kinase inhibitors | NOVARTIS AG | 2010-06-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | LMNA 3806/4885POLB 3390/4885AR 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.